Myroides odoratus as an unusual urinary tract infection pathogen in immunosuppressed patient
Abstract
Rev Esp Quimioter 2022;35(6): 577-578 577 The susceptibility profile reported was as follows: susceptible to levofloxacin (MIC 128 mg/L), ceftazidime (MIC ≥64 mg/L), aztreonam (MIC ≥64 mg/L), imipenem (MIC ≥16 mg/L), meropenem (MIC ≥16 mg/L), gentamicin (MIC ≥16 mg/L), tobramycin (MIC ≥16 mg/L), amikacin (MIC ≥64 mg/L), and fosfomycin (MIC ≥32 mg/L). The patient was treated with sulfamethoxazole 800 mg/trimethoprim 600 mg/12 h for 7 days. He responded favorably to treatment and had no further symptoms. No new post-treatment control sample was sent. Myroides odoratus as an unusual urinary tract infection pathogen in immunosuppressed patient
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.